1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Most relevant
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
Delayed Australian Stock Exchange  -  10:10 2022-07-05 pm EDT
0.1300 AUD   -3.70%
07/04ResApp Health Gets Australian, Japanese Patents for Cough Detection Technology
MT
06/20ResApp Health Limited Announces Results from Data Confirmation Study
CI
06/16RESAPP HEALTH : Application for quotation of securities - RAP
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about RESAPP HEALTH LIMITED
07/04ResApp Health Gets Australian, Japanese Patents for Cough Detection Technology
MT
06/20ResApp Health Limited Announces Results from Data Confirmation Study
CI
06/16RESAPP HEALTH : Application for quotation of securities - RAP
PU
06/14Pfizer Sweetens Offer to Acquire Australian ResApp Health
MT
06/13RESAPP HEALTH : Increased Scheme Consideration from Pfizer
PU
04/25TRANSCRIPT : ResApp Health Limited, Q3 2022 Earnings Call, Apr 26, 2022
CI
04/25RESAPP HEALTH : Quarterly Activities Report and Appendix 4C
PU
04/11Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited for appro..
CI
04/10RESAPP HEALTH : Proposed Acquisition of ResApp Health by Pfizer
PU
04/07TRANSCRIPT : ResApp Health Limited - Special Call
CI
04/01RESAPP HEALTH : Dartford and Gravesham NHS Trust to pilot ResAppDx
PU
03/31ResApp Health Signs Deal for Pilot Testing of Respiratory Diagnostic App in the UK
MT
03/31ResApp Health Limited Signs One Year Agreement with the Dartford and Gravesham National..
CI
03/24Kairos Minerals Ltd - Board Update
AQ
03/22ResApp Health's Cough-based Diagnostic Test Achieves 92% Sensitivity Rate for COVID-19 ..
MT
03/21TRANSCRIPT : ResApp Health Limited - Special Call
CI
03/21RESAPP HEALTH : COVID-19 Investor Presentation
PU
03/21RESAPP HEALTH : announces positive results for a new novel smartphone-based COVID-19 scree..
PU
03/21ResApp Health Limited Announces Positive Results of Covid-19 Screening Test
CI
02/24ResApp Health Limited Reports Earnings Results for the Half Year Ended December 31, 202..
CI
02/15RESAPP HEALTH : Health Teams to launch ResAppDx on aged care telehealth platform
PU
02/14Resapp Health, Health Teams to Launch ResAppDx on Aged Care Telehealth Platform
MT
02/13Health Teams to Launch ResAppDx on Aged Care Platform
CI
02/02RESAPP HEALTH : Cough analysis patent granted in China
PU
01/31China Grants Patent Application for Resapp Health's Cough Analysis Apparatus; Shares Ri..
MT
01/27TRANSCRIPT : ResApp Health Limited, Q2 2022 Earnings Call, Jan 28, 2022
CI
01/26RESAPP HEALTH : Further international appointments to COVID-19 Scientific Advisory Board
PU
01/26ResApp Health Limited Announces Appointments to Covid-19 Scientific Advisory Board
CI
01/24RESAPP HEALTH : ResAppDx goes live with Doctors on Demand in Australia
PU
01/23ResApp Health's Respiratory Diagnostic App Goes Live on Telehealth Provider's Platform
MT
01/23ResApp Health Limited Goes Live with Doctors on Demand in Australia
CI
01/19RESAPP HEALTH : Binding LOI signed with Homify to launch ResAppDx in the Philippines
PU
01/19ResApp Health Signs Deal to Integrate Respiratory Diagnostic App into Philippine Telehe..
MT
01/19ResApp Health Limited Signs LOI with Homify to Launch ResAppDx in the Philippines
CI
01/16RESAPP HEALTH : New publication highlights use of ResAppDx in a COVID-19 fever clinic
PU
01/13RESAPP HEALTH : Notification regarding unquoted securities - RAP
PU
01/09ResApp Health Completes Recruitment for US COVID-19 Cough Study
MT
01/09ResApp Health Limited Completes Recruitment in its U.S. Covid-19 Clinical Study
CI
01/06ResApp Health's Respiratory Diagnostic Test Goes Live in Indonesia
MT
2021ResApp Health Signs Distribution Deal for Respiratory App in Emerging Markets; Shares F..
MT
2021RESAPP HEALTH : Distribution agreement with Sanrai International for emerging markets
PU
2021Resapp Health Limited Enters into Three-Year Distribution Agreement with Sanrai Interna..
CI
2021ResApp Health Secures Tax Rebate for R&D Activities
MT
2021RESAPP HEALTH : receives $818,826 in R&D tax incentive refund
PU
2021RESAPP HEALTH : Establishes COVID-19 Scientific Advisory Board
PU
2021ResApp Health Sets Up COVID-19 Advisory Board
MT
2021ResApp Health Limited Announces the Establishment of COVID-19 Scientific Advisory Board
CI
2021TRANSCRIPT : ResApp Health Limited - Shareholder/Analyst Call
CI
2021RESAPP HEALTH : receives world's first regulatory approvals for cough counter smartphone a..
PU
2021ResApp Health Secures Australian, European Approvals for Cough Counter App; Shares Rise..
MT
2021ResApp Receives Regulatory Approvals for Cough Counter
CI
2021ResApp Health Completes Recruitment for COVID-19 Study in India
MT
2021RESAPP HEALTH : completes COVID-19 study recruitment in India
PU
2021ResApp Health Limited Completes COVID-19 Study Recruitment in India
CI
2021RESAPP HEALTH : New publication highlights challenges of diagnosing acute respiratory dise..
PU
2021Resapp Health Limited Announces Publication of Clinical Study Data Analysed from its Br..
CI
2021Resapp Health Signs Deal with Johnson & Johnson Arm for Use of App in a Clinical Trial;..
MT
2021RESAPP HEALTH : secures contract with global pharmaceutical company
PU
2021ResApp Health Limited Secures Contract with Janssen Pharmaceutica NV
CI
2021RESAPP HEALTH : Partnership with Carepath for passive in-home monitoring of COPD patients
PU
2021ResApp Health Signs Deal to Integrate ResAppDx into Carepath Technologies Platform
MT
2021ResApp Health Limited Signs Joint Development and Pilot Agreement with Carepath Technol..
CI
2021ResApp Health Secures Approval to Modify COVID-19 Study in the US; Shares Rise 4%
MT
2021RESAPP HEALTH : IRB approval for US COVID-19 study modification
PU
2021ResApp Health Limited Receives Institutional Review Board Approval to Modify its Us-Bas..
CI
2021TRANSCRIPT : ResApp Health Limited, Q1 2022 Earnings Call, Oct 28, 2021
CI
2021RESAPP HEALTH : Expands Enrollment for COVID-19 Screening Trial in India
MT
2021RESAPP HEALTH : COVID-19 Clinical Studies Update
PU
2021ResApp Health Limited Announces COVID-19 Clinical Studies Update
CI
2021RESAPP HEALTH : ReAapp Health Seeks US FDA Nod for Apnea Assessment Mobile App
MT
2021RESAPP HEALTH : announces FDA 510(k) submission for SleepCheckRx
PU
2021Resapp Announces FDA 510(K) Submission for Sleepcheckrx
CI
2021RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
MT
2021RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
PU
2021Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
CI
1  2  3  4  5Next
Upcoming event on RESAPP HEALTH LIMITED